A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Conditions

• Non-small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Atezolizumab — DRUG
  Atezolizumab 1680 mg every 4 weeks (Q4W) will be administered IV on Day 1 of each 28-day cycle.
• Tiragolumab — DRUG
  Tiragolumab 840 mg Q4W will be administered IV on Day 1 of each 28-day cycle.
• Durvalumab — DRUG
  Durvalumab will be administered based on weight at 10 mg/kg IV every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle, or will be administered at a fixed dose of 1500 mg IV every 4 weeks (Q4W) (for participants whose weight \>/= 30 kg) on Day 1 of each 28-day cycle.

Study Details

The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression.

Key Dates

Start date

Aug 24, 2020

Status verified

May 2026

Primary completion

May 27, 2025

Completion

Jul 31, 2025

Study Design

Enrollment

829 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Atezolizumab + Tiragolumab
  Participants will receive atezolizumab administered intravenously (IV) on Day 1 of each 28-day cycle followed by tiragolumab administered IV on Day 1 of each 28-day cycle for a maximum of 13 cycles.
• Active Comparator: Durvalumab
  Participants will receive durvalumab administered IV during each 28-day cycle for a maximum of 13 cycles.

Primary Outcome Measure

Progression-free Survival (PFS), as Assessed by an Independent Review Facility (IRF) in Programmed Death-ligand 1 (PD-L1) Positive Analysis Set (PPAS) [ Time Frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months) ]

Locations (25)

Related coverage on Hipa.ai

• Atezolizumab + Tiragolumab Phase 3 NSCLC Trial Shows Similar Efficacy to…
  Atezolizumab · Jun 3, 2026 · ClinicalTrials.gov
• Atezolizumab Phase 3 Trial for NSCLC Reaches Primary Completion
  Atezolizumab · May 27, 2025 · ClinicalTrials.gov

Find similar trials in Palo Alto, CA

Related Studies

• ROSE for Improved Molecular Marker Testing Via EBUS
  Enrolling By Invitation · Johns Hopkins University · Chicago, Illinois
• A Study of NX-1607 in Adults With Advanced Malignancies
  PHASE1 · Recruiting · Nurix Therapeutics, Inc. · Duarte, California
• Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
  PHASE1 · Recruiting · Exelixis · Phoenix, Arizona
• Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
  PHASE1/PHASE2 · Recruiting · Revolution Medicines, Inc. · Orange, California